JP2013507337A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507337A5
JP2013507337A5 JP2012532587A JP2012532587A JP2013507337A5 JP 2013507337 A5 JP2013507337 A5 JP 2013507337A5 JP 2012532587 A JP2012532587 A JP 2012532587A JP 2012532587 A JP2012532587 A JP 2012532587A JP 2013507337 A5 JP2013507337 A5 JP 2013507337A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
component comprises
glycol
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012532587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507337A (ja
JP5764792B2 (ja
Filing date
Publication date
Priority claimed from EP09012724A external-priority patent/EP2308468A1/en
Application filed filed Critical
Publication of JP2013507337A publication Critical patent/JP2013507337A/ja
Publication of JP2013507337A5 publication Critical patent/JP2013507337A5/ja
Application granted granted Critical
Publication of JP5764792B2 publication Critical patent/JP5764792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012532587A 2009-10-08 2010-10-07 マクロライド免疫抑制剤を含む新規な医薬組成物 Active JP5764792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09012724.2 2009-10-08
EP09012724A EP2308468A1 (en) 2009-10-08 2009-10-08 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
PCT/EP2010/064965 WO2011042485A1 (en) 2009-10-08 2010-10-07 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Publications (3)

Publication Number Publication Date
JP2013507337A JP2013507337A (ja) 2013-03-04
JP2013507337A5 true JP2013507337A5 (https=) 2013-11-07
JP5764792B2 JP5764792B2 (ja) 2015-08-19

Family

ID=41435414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532587A Active JP5764792B2 (ja) 2009-10-08 2010-10-07 マクロライド免疫抑制剤を含む新規な医薬組成物

Country Status (12)

Country Link
US (1) US8574562B2 (https=)
EP (2) EP2308468A1 (https=)
JP (1) JP5764792B2 (https=)
KR (1) KR101790257B1 (https=)
CN (1) CN102510752B (https=)
AU (1) AU2010305404B2 (https=)
BR (1) BR112012007332B1 (https=)
CA (1) CA2774720C (https=)
ES (1) ES2552803T3 (https=)
IN (1) IN2012DN01559A (https=)
MX (1) MX2012003800A (https=)
WO (1) WO2011042485A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
AU2012274367A1 (en) * 2011-06-23 2014-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
CN103830178B (zh) * 2014-03-18 2017-01-11 深圳劲创生物技术有限公司 一种蒜氨酸微乳及其制备方法和应用
EP3334416A1 (en) * 2015-08-11 2018-06-20 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
CA3020157C (en) * 2016-04-04 2024-01-16 Drug Delivery Solutions Limited Topical composition comprising tacrolimus
US20200323793A1 (en) * 2016-06-03 2020-10-15 Avexxin As Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
CN106074386A (zh) * 2016-08-31 2016-11-09 佛山市弘泰药物研发有限公司 一种依维莫司自微乳制剂及其制备方法
CN109789111B (zh) 2016-09-21 2021-11-16 埃维克辛公司 药物组合物
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
KR20210141448A (ko) 2018-12-27 2021-11-23 서피스 아프샐믹스 인코포레이티드 안구 표면 질환을 치료하기 위한 안과용 약학 조성물 및 방법
WO2021148619A1 (en) * 2020-01-22 2021-07-29 Bausch Health Ireland Limited Topical compositions comprising a macrolide immunosuppressant
TWI769745B (zh) * 2021-03-19 2022-07-01 國泰醫療財團法人國泰綜合醫院 醫藥組成物與製藥用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
US12310981B2 (en) 2021-05-10 2025-05-27 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan
KR102727647B1 (ko) * 2023-11-28 2024-11-08 장병모 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175235B1 (da) * 1987-11-09 2004-07-19 Novartis Ag Ny anvendelse af azatricycloderivater og farmaceutiske præparater med indhold deraf
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2315216B (en) * 1993-10-05 1998-10-14 Ciba Geigy Ag Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
CN100335063C (zh) * 1994-10-26 2007-09-05 诺瓦蒂斯有限公司 药物组合物
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
ATE468107T1 (de) * 2001-11-01 2010-06-15 Yissum Res Dev Co Verfahren und zusammensetzung zur behandlung von trockenen augen
IL162496A0 (en) * 2001-12-14 2005-11-20 Jagotec Ag Pharmaceutical compositions containing cyclosporin
BRPI0513395A (pt) * 2004-07-16 2008-05-06 Novartis Ag uso de um esteróide para aumentar a permeabilidade cutánea
AU2005304035B2 (en) * 2004-11-09 2010-07-22 Santen Sas Ophthalmic oil-in-water type emulsion with stable positive zeta potential
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
WO2006123354A2 (en) * 2005-02-02 2006-11-23 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions

Similar Documents

Publication Publication Date Title
JP2013507337A5 (https=)
US11622945B2 (en) Topical pharmaceutical compositions
US20100063008A1 (en) Gelatinous elastomer compositions
US9056086B2 (en) Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof
CA2816203C (en) Aripiprazole compositions and methods for its transdermal delivery
US8992994B2 (en) Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
CN1767826A (zh) 包括免疫抑制剂的用于治疗皮肤疾病的药物组合物
JP7502242B2 (ja) 状態を予防及び治療するための組成物及び方法
Alamoudi et al. A comparative dermatokinetic evaluation of thymoquinone-loaded nanoemulsion gel for enhanced wound healing and anti-inflammatory efficacy
US9789123B2 (en) Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
KR20220008721A (ko) 카라기난을 포함하는 피부 외용 연고제 조성물
RU2859799C1 (ru) Средство для лечения воспалительных дерматозов, в том числе осложненных бактериальной и/или грибковой инфекцией
WO2019002367A1 (en) TOPICAL COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
Mittal et al. Niosomes-Based Pharmacotherapy for the Management of Psoriasis
TR2022020852A2 (tr) Propoli̇s ve dekspantenol nanoemülsi̇yonlarini i̇çeren hi̇drojel ve organojel formülasyonlari
EP2547312A2 (en) Microparticles of epidermal lipids containing polyalcohol for the preparation of cosmetic and pharmaceutical compositions
HK1260924A1 (en) Topical formulations and uses thereof
HK1260924B (en) Topical formulations and uses thereof